[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hip-arthropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hip-arthropathy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,43,68,93,117,149,176,206,227,248,276,300,323,351,374,405,433,459],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100606855","phase-4-peng-vs-l-espb-with-s-espb-for-analgesia-in-total-hip-arthroplasty-100606855",false,"NCT07180979","PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty","Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 65 years\n* ASA physical status I-III\n* Elective unilateral THA via posterior or lateral approach\n* Informed consent provided\n\nExclusion Criteria:\n\n* Allergy to study drugs (ropivacaine, dexamethasone)\n* Chronic opioid use (\\>30 MME\u002Fday)\n* Coagulopathy or infection at the injection site\n* BMI \\> 40 kg\u002Fm²\n* Pre-existing motor weakness or neuropathy in the affected limb\n* Cognitive impairment precluding informed consent","ALL","65 Years","100 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to evaluate whether different types of regional anesthesia can improve pain control and functional recovery after total hip arthroplasty in adult patients undergoing elective hip replacement surgery.\n\nThe main questions it aims to answer are:\n\nDoes the PENG block reduce opioid use in the first 48 hours after surgery more effectively than the combined L-ESPB + S-ESPB technique? Which method provides better pain relief, preserves muscle strength, and supports earlier mobilization? Researchers will compare the Pericapsular Nerve Group (PENG) block with the combination of Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB + S-ESPB) to see which provides better pain control, fewer side effects, and faster recovery.\n\nParticipants will:\n\nBe randomly assigned to receive one of the two types of ultrasound-guided regional anesthesia Undergo standard hip replacement surgery under spinal anesthesia Be monitored for pain scores, opioid use, time to first walking, muscle strength, satisfaction, and side effects over the first 48 hours after surgery.",[27,28,29],"Hip Osteoarthritis","Hip Arthropathy","Hip Pain Chronic","RECRUITING","2026-05-06",{"date":33,"type":34},"2026-05-07","ACTUAL",{"date":36,"type":34},"2025-09-15",{"date":38,"type":21},"2026-11-30",{"name":40,"class":41},"Poznan University of Medical Sciences","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100588490","cryoneurolysis-in-patients-awaiting-total-hip-and-knee-arthroplasty-100588490","NCT06942078","Cryoneurolysis in Patients Awaiting Total Hip and Knee Arthroplasty","Cryoneurolysis as an Interim Pain Control Strategy in Patients Awaiting Total Hip and Knee Arthroplasty: a Prospective Observational Study","Inclusion Criteria:\n\n* Currently awaiting THA or TKA (have signed consent for surgery)\n* Osteoarthritis as a primary diagnosis for THA or TKA\n* Currently taking regular daily opioids for at least one month\n* No allergies to local aesthetics\n* Speaks and understands English\n* Over 18 years old\n* Lives within a 1-hour distance of the hospital where the study is taking place or willing to travel to the hospital for the interventions and follow up.\n\nExclusion Criteria:\n\n* If surgery is expected to be completed within 1 month of the intervention as this would limit our ability to evaluate the effectiveness of the cryoneurolysis procedure\n* Allergies to local anesthetics\n* Inability to communicate with investigators\n* Opioid use disorder\n* History of severe psychiatric or medical conditions which hinder effective communication\n* Living more than 1 hour away from the hospital where the study is taking place or unable to travel to the hospital for the interventions and follow up\n* Body mass Index (BMI) ≥40\n* Any contraindications specific to percutaneous cryoneurolysis such as history of bleeding diathesis, any active infections at the procedural site, cold urticaria, cryofibrinogenemia, cryoglobulinemia, paroxysmal cold hemoglobinuria, or Raynaud's disease (see Ilfeld \\& Finneran, 2020)\n* Use of therapeutic anticoagulation\n* Diagnosis of Non-Osteoarthritis as the cause for THA or TKA\n* Other chronic pain condition which patients may be taking opioids to control the pain (e.g. Fibromyalgia or Complex Regional Pain Syndrome)\n* Less than 50% reduction in pain with diagnostic blocks using 0.5% bupivacaine","18 Years",{"count":52,"type":21},30,[54],"NA","During the COVID-19 pandemic, there was a drastic increase in surgical wait times across Canada, notably for patients awaiting total knee and hip arthroplasty. Currently the average wait time for total hip arthroplasty (THA) in Alberta is 16 weeks with the 90th percentile of wait times being 47 weeks. The average wait for total knee arthroplasty (TKA) in Alberta is 20 weeks with the 90th percentile of wait times being 60 weeks. As the waitlist for these surgeries grows and with limited resources to increase the number of surgeries being performed, there is a critical need for strategies to manage the pain experienced by patients during these long waiting periods.\n\nMany patients awaiting surgery are placed onto long-term opioid therapy to manage their pain. There are, however, significant risks associated with the extended use of opioids for pain management, such as addiction, opioid abuse, increased risk of overdose, increased risk of fractures, and increased risk of adverse cardiac events. Recognizing these risks, different strategies need to be employed to attempt to minimize the opioid burden faced by those waiting for surgery. One potential strategy is to utilize regional anesthesia for analgesia rather than relying on opioids. Regional anesthesia with nerve blocks using local anesthetic has been used in the management of preoperative pain for patients awaiting surgery for hip fracture and has been shown to be effective in reducing pain, opioid use, and the risk of serious adverse effects. However, for patients with hip fractures, their surgery usually occurs within 36 hours due to significant risks which occur beyond that timeframe. For patients waiting for THA and TKA, the surgical wait time could be weeks to months. Providing daily nerve blocks or even weekly catheters for an individual waiting up to a year for surgery is not sustainable and carries significant risks with repeated injections. New regional anesthesia techniques lasting a longer period of time are needed.\n\nOne promising intervention is to utilize cryoneurolysis. Cryoneurolysis involves treating targeted nerves using extremely low temperatures. This disrupts nerve conduction and pain impulses. Importantly, connective tissue components of the nerve are left intact allowing for regeneration over time. Because of this, cryoneurolysis is a well-established treatment for chronic and acute pain due to its effectiveness and low risk safety profile. While cryoneurolysis is well-established in its use treating chronic and surgical pain, one limitation is that it is focused primarily on postoperative pain. Our study intends to primarily evaluate the efficacy of cryoneurolysis as a preoperative pain management intervention. Establishing the use of cryoneurolysis for preoperative pain will provide a valuable resource for reducing the pain patients experience while awaiting surgery, leading to decreased opioid use and improved overall well-being. The investigators will be recruiting 30 participants total (15 having TKA and 15 having THA) that will be given cryoneurolysis while waiting for their surgery.",[28,57],"Knee Arthropathy","NOT_YET_RECRUITING","2026-04-28",{"date":61,"type":34},"2026-05-04",{"date":63,"type":21},"2026-06-01",{"date":65,"type":21},"2028-12-31",{"name":67,"class":41},"University of Calgary",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100512729","hip-prospective-study-100512729","NCT05956236","Hip Prospective Study","Hip Prospective Study: Long-term Post-market Clinical Follow-up on the Use of SERF Hip Prostheses","Inclusion Criteria:\n\n* Male or female adults\n* Planned to be implanted with investigational medical devices per the IFUs:\n\n  * Implantation in skeletally mature adults (usually aged 60-65 and over), with an extremely painful and\u002For disabled joint and insufficiently improved by alternative treatment options after an observation period lasting from a few weeks to a few months\n  * Implantation of investigational medical devices as integrated systems (all components from SERF, no component from another manufacturer)\n  * For an intended purpose and indication listed in the IFUs\n* Affiliated to French social security\n* Who provided a dated and signed informed consent form\n\nExclusion Criteria:\n\n* Patient protected by a French legal measure\n* Patient not able to express his\u002Fher consent as deemed by the investigator\n* Patient deprived of liberty or hospitalized without consent\n* Pregnant or breastfeeding women\n* Patient contraindicated to investigational medical devices implantation per the IFUs\n* Patient contraindicated to radiographic follow-up\n* Patient a priori not able to meet the follow-up visits as deemed by the investigator\n* Patient not able to fulfil a self-assessment questionnaire as deemed by the investigator.",{"count":76,"type":21},5000,"OBSERVATIONAL","In an evaluation report dated 2014, the HAS (Haute Autorité de Santé -French National Authority for Health) highlights that long-term clinical data on hip prostheses are needed in the context of the French healthcare system. In addition, per the European Regulation 2017\u002F745, medical devices manufacturers shall conduct Post-Market Clinical Follow-up (PMCF) on their devices or provide a justification why PMCF is not applicable.\n\nTherefore, as part of the PMCF process of their hip prostheses, SERF wants to conduct a PMCF investigation to ensure the long-term real-life performance, safety and benefits of these prostheses.\n\nHiPS is a non-comparative, prospective, multicentric, national, 15-year follow-up clinical investigation.",[28],[81,82],"Hip arthropalsty","Hip Prosthesis","2026-04-09",{"date":85,"type":34},"2026-04-14",{"date":87,"type":34},"2023-04-24",{"date":89,"type":21},"2046-04",{"name":91,"class":92},"Societe dEtude, de Recherche et de Fabrication","INDUSTRY",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":42},"100545981","marrow-cellution-vs-traditional-bma-harvest-project-100545981","NCT06388993","Marrow Cellution™ vs. Traditional BMA Harvest Project","Comparison of the Constituents of Bone Marrow Aspirate and Autologous Protein Solution Collected With a Traditional and a Novel System","Inclusion Criteria:\n\n* patients aged 18 - 50\n* patients undergoing hip arthroscopy for subchondral bone cysts and\u002For avascular necrosis\n\nExclusion Criteria:\n\n* patients with a history of hematologic issues including anemia and sickle cell anemia\n* patients with a history of leukemia, lymphoma, or other bone marrow related diseases\n* patients with diabetes\n* patients with a history of bone marrow aspirate","50 Years",{"count":102,"type":21},6,[54],"Six patients with diagnosed bone loss of the hip who have consented to minimally invasive repair will be approached to participate in the study. Participants will have the liquid portion of bone marrow collected using the Zimmer Biomet Biocue system, which is the standard system used by physicians at The Ohio State University, and the novel Marrow Cellutions system™. Bone marrow liquid will be collected from the surgical hip using the Zimmer Biomet Biocue system, and the Marrow Cellutions system™ will be used to collect bone marrow liquid from the non-surgical hip. Following collection, the bone marrow liquid will be processed using the respective systems to concentrate the cells and molecules found in the bone marrow liquid. As part of the standard of care for this arthroscopic procedure, concentrated bone marrow liquid processed using the Zimmer Biomet Biocue system will be delivered to the surgical site as an adjunct to promote healing. Concentrated bone marrow liquid prepared with the Zimmer Biomet Biocue system is given as part of the standard of care for patients undergoing minimally invasive treatment for bone loss of the hip; therefore, the target population for this study are individuals between the ages of 18-50 years with confirmed bone loss of the hip who have consented to minimally invasive repair. In addition to the concentrated bone marrow liquid prepared using the Zimmer Biomet Biocue system, patients will also have bone marrow liquid collected from the non-surgical hip using the Marrow Cellutions™ system. Only concentrated bone marrow liquid produced with the Zimmer Biomet Biocue system will be given to the patient. All concentrated bone marrow liquid produced with the Marrow Cellutions™ system will be sent to the laboratory for analysis. Additionally, white blood cells will be concentrated into an autologous protein solution (APS) using the Zimmer Biomet Plasmax system from blood collected using a routine blood draw. All protein solution produced will be sent to the laboratory for analysis. No protein solution will be given to the patient. As the bone marrow liquid collection using the Marrow Cellutions™ system and the blood draw to produce protein solution using the Zimmer Biomet Plasmax system are being performed for research,",[28,106,107],"Avascular Necrosis of Bone","Subchondral Cysts","2026-03-26",{"date":110,"type":34},"2026-04-01",{"date":112,"type":34},"2024-03-25",{"date":114,"type":21},"2026-12-31",{"name":116,"class":41},"Ohio State University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":42},"100614824","pericapsular-nerve-group-peng-block-combined-with-lateral-femoral-cutaneous-nerve-lfcn-block-or-wound-infiltration-for-postoperative-analgesia-in-anterior-approach-total-hip-arthroplasty-a-randomized-controlled-trial-100614824","NCT07284615","Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial","Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration (WI) Combined With Pericapsular Nerve Group (PENG) Block for Analgesia in Elective Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial","Peng_lfcn\u002FWI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Elective total hip arthroplasty\n* Spinal (subarachnoid) anesthesia\n* Written informed consent provided by the patient or by the legal guardian, if appointed\n\nExclusion Criteria:\n\n* INR \\> 1.5\n* aPTT \\> 1.5\n* Platelet count \\\u003C 75,000\u002Fmm³\n* Signs suggestive of infection at the puncture site\n* Absence of informed consent to the procedure\n* Documented or suspected allergy to local anesthetics",{"count":126,"type":21},102,[54],"This prospective, randomized controlled trial aims to compare two multimodal regional anesthesia strategies for postoperative analgesia in elective total hip arthroplasty (THA) performed via anterior approach. Patients will be randomized to receive either a Pericapsular Nerve Group (PENG) block combined with a Lateral Femoral Cutaneous Nerve (LFCN) block, or a PENG block combined with wound infiltration (WI).\n\nThe primary outcome is postoperative pain intensity at rest, measured by Numerical Rating Scale (NRS) at 6 hours after surgery. Secondary outcomes include dynamic pain scores at 6, 24, and 48 hours, total opioid consumption, time to first rescue analgesia, quadriceps strength, hip flexion angle, length of stay, and adverse events.\n\nAll procedures are routinely used in clinical practice and carry minimal additional risk. Safety will be continuously monitored by the Principal Investigator and the study team according to an internal Safety Monitoring Plan.",[130,28,131,132,133,134,135],"Arthropathy of Hip","Locoregional Anesthesia","Complication of Anesthesia","Regional Anesthesia Morbidity","Hospital Stay, Length of Stay in Hospital From Time of Surgery Till Discharge","Opioid Consumption",[137,138,139],"Postoperative muscle weakness","ERAS","Regional Block","2026-03-21",{"date":142,"type":34},"2026-03-25",{"date":144,"type":34},"2026-01-26",{"date":146,"type":21},"2026-11",{"name":148,"class":41},"Ospedale Edoardo Bassini",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100560321","knee-hip-surgery-wait-list-support-program-100560321","NCT06575621","Knee-hip Surgery Wait-list Support Program","Re-imagining Hip and Knee Arthroplasty Wait-list in Nova Scotia: Pre-surgery Support Program","Inclusion Criteria:\n\n* On surgery wait list for total hip or knee arthroplasty at Valley Regional Hospital\n* 18+ and able to provide informed consent\n* Anticipated surgery time 8-16 weeks after the study start date\n\nExclusion Criteria:\n\n* Any contraindications or exclusions identified through the assessment process that are outside thresholds for acceptable surgery risk",{"count":157,"type":21},50,[54],"This project will outline a pre-surgery support program that identifies risk factors related to poor surgical outcomes and recommends actions to improve these before surgery.\n\nThe main questions this study attempts to answer are:\n\n1. Is a formalized knee-hip pre-surgery support program feasible, measured by recruitment rate, adherence, and completion rate?\n2. Does the support program improve surgical risk factors including hemoglobin A1c (HB A1C), blood pressure, hemoglobin, estimated glomerular filtration rate (eGFR), frailty score, and physical fitness and function (measured with the 2-minute step test and 30s second sit to stand test)?\n\nParticipants will participate in education, medical navigation, and exercise.",[57,28],[162,163,164,165,166],"surgery","knee","hip","exercise","risk factors","2026-03-19",{"date":169,"type":34},"2026-03-20",{"date":171,"type":21},"2026-06-15",{"date":173,"type":21},"2027-08-30",{"name":175,"class":41},"Nova Scotia Health Authority",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":77,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":102},"100587144","radiographic-stability-of-hip-prosthesis-prior-to-revision-surgery-100587144","NCT06924567","Radiographic Stability of Hip Prosthesis Prior to Revision Surgery","The Accuracy of CT-based Implant Movement for the Evaluation of Cup and Stem Stability, When Plain Radiography is Not Conclusive for Loosening, in Patients Scheduled for Revision Hip Arthroplasty. A Multicenter Study","MULTICIMA","Inclusion criteria:\n\n* Patient scheduled for revision THA due to aseptic loosening.\n* One component (cup or stem) has no convincing loosening signs, based on the preoperative plain radiographs and clinical assessment by the attending surgeon.\n* Radiographs not older than 8 weeks prior to surgery.\n\nExclusion criteria:\n\n* Both cup and stem have been preoperatively evaluated as loose\n* Instability with repeating dislocation of the THA\n* Non-aseptic revision surgery, based on preoperative work up.\n* The scheduled revisionsurgery is cancelled.",{"count":185,"type":21},600,"2 Months","The goal of this validation study is to compare the preoperative implant stability, assessed by Implant Movement Analysis (IMA), provocation dual CT scans, with the intraoperative stability evaluation in revision hip arthoplasty. The main question it aims to answer is:\n\nDoes IMA reflect the intraoperative clinical evaluation of implant stability? Participants scheduled for revision hip arthoplasty will undergo IMA preoperativelly in addition to rutine clinical work up. During revision arthoplasty, a surgeon blinded to the IMA results will assess clinically the stability of the hip prosthesis. IMA will be compared with the intraoperative findings to assess IMAs sensitivity and specificity",[189,28],"Loosening, Prosthesis",[191,192,193,194,195,196],"implant stabilty","THA","radiographic evaluation","IMA","Implant Movement Analysis","Revision THA","2026-03-10",{"date":199,"type":34},"2026-03-12",{"date":201,"type":21},"2026-09-15",{"date":203,"type":21},"2029-12-31",{"name":205,"class":41},"Georgios Tsikandylakis, MD PhD",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":42},"100429731","optimized-mri-of-patients-with-hip-arthroplasty-100429731","NCT04875884","Optimized MRI of Patients With Hip Arthroplasty","Inclusion Criteria:\n\n* Patients aged ≥ 18 with unilateral symptomatic (e.g. pain) total hip arthroplasty\n* Referred for MRI examination at the discretion of the treating physician\n* Provision of signed and dated informed consent form\n* No metal hardware in the body including contralateral hip arthroplasty\n* No contraindication to MRI: defined as claustrophobia or presence of other MRI-incompatible devices\n\nExclusion Criteria:\n\n* History of revision hip arthroplasty\n* Pregnancy (self-reported, or self-suspected)\n* Hip arthroplasty surgery within one year of enrollment\n* Clinical indication to administer intravenous contrast material during MRI","99 Years",{"count":214,"type":21},22,[54],"This is a single-center single-arm clinical trial with a paired design which compares the effectiveness of 3T MRI with (modified) and without (standard) radiofrequency pulse polarization optimization in reducing metal-related artifacts in patients with hip arthroplasty implants.",[28],"2026-03-02",{"date":220,"type":34},"2026-03-04",{"date":222,"type":34},"2022-08-11",{"date":224,"type":21},"2027-12-30",{"name":226,"class":41},"NYU Langone Health",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":17,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":42},"100452729","interest-of-a-highly-cross-linked-polyethylene-acetabular-component-doped-with-vitamin-e-in-total-hip-arthroplasty-of-the-young-and-active-subject-100452729","NCT05175300","Interest of a Highly Cross-linked Polyethylene Acetabular Component Doped With Vitamin E in Total Hip Arthroplasty of the Young and Active Subject","ICARE","Inclusion Criteria:\n\n* Patient aged 18 to 65 years,\n* Who have signed their consent to participate in the study,\n* For whom an indication for total hip arthroplasty has been given\n\nExclusion Criteria:\n\n* History of hip surgery\n* Indication for a dual mobility prosthesis (obese patient, dynamic spino-pelvic anomaly)\n* Hip dysplasia\n* Inflammatory rheumatic disease or any other progressive concomitant condition that may impact the patient's vital or functional prognosis\n* Sequelae of neurological disease or stroke\n* Pregnant or breastfeeding women\n* Mental deficiency or any other reason that may hinder the understanding or the strict application of the protocol\n* Patient likely not to return for follow-up visits\n* Patient already included in another therapeutic study protocol\n* Patient under court protection, guardianship or curatorship.",{"count":235,"type":21},100,[54],"Interest of a highly cross-linked polyethylene acetabular component doped with vitamin E in total hip arthroplasty of the young and active subject.",[28],"2025-11-25",{"date":241,"type":34},"2025-12-03",{"date":243,"type":34},"2023-03-24",{"date":245,"type":21},"2032-03",{"name":247,"class":41},"GCS Ramsay Santé pour l'Enseignement et la Recherche",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":261,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":42},"100482033","anterior-iliopsoas-muscle-space-block-versus-supra-iliac-anterior-quadratus-lumborum-block-in-total-hip-arthroplasty-100482033","NCT05556759","Anterior Iliopsoas Muscle Space Block Versus Supra-iliac Anterior Quadratus Lumborum Block in Total Hip Arthroplasty","Anterior Iliopsoas Muscle Space Block Versus Supra-Iliac Anterior Quadratus Lumborum Block for Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient acceptance.\n* Age 50-80 years old.\n* BMI ≤ 30 kg\u002Fm2\n* ASA I - III.\n* Elective total hip arthroplasty under general anesthesia.\n\nExclusion Criteria:\n\n* History of allergy to the LA agents used in this study\n* Skin lesion at the needle insertion site,\n* Those with bleeding disorders, sepsis, liver disease, and psychiatric disorders\n* Pre-existing neurological deficit in the lower extremity\n* History of chronic pain and taking analgesics\n* History of cognitive dysfunction or mental illness","80 Years",{"count":257,"type":21},72,[54],"Approximately 1.66 million hip fractures happen in a year worldwide. About 95% of these fractures happen in individuals older than 60 years. Surgical treatment involving THA is considered the best option for patients with hip fractures and those with degenerative changes in the hip joint, especially in the elderly, however, it is associated with moderate to severe postoperative pain.\n\nPain is one of the main factors limiting ambulation, increasing the risk of thromboembolism by immobility, and causing metabolic changes that affect other systems. Therefore, individualized pain management with the use of appropriate analgesia techniques is of paramount importance. Moreover, early intervention of rehabilitation aiming at a better postoperative recovery may reduce the length of hospital stay and return to daily. Effective pain management is one of the crucial components of enhanced recovery after surgery (ERAS).\n\nNumerous regional anesthetic techniques have been used to provide analgesia following THA, including intrathecal morphine, epidural analgesia, fascia iliaca block, lumber plexus block, sacral plexus block, and local infiltration analgesia, however, each of these techniques has specific limitations that prevent them from being the analgesic technique of choice for THA.\n\nUp to investigators' knowledge, there is no study done to compare the supra-iliac approach to the anterior QL block versus the Anterior iliopsoas muscle space block as pre-emptive analgesia in patients undergoing THA under general anesthesia",[28],[262,263,264,265],"Anterior iliopsoas muscle space block","suprailiac anterior quadratus lumborum block","analgesia","hip arthroplasty","2025-07-14",{"date":268,"type":34},"2025-07-15",{"date":270,"type":34},"2022-09-30",{"date":272,"type":21},"2025-11-01",{"name":274,"class":275},"Zagazig University","OTHER_GOV",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":42},"100594718","phase-4-peng-with-lfcb-vs-esp-blocks-for-pediatric-hip-surgery-100594718","NCT07023094","PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery","Comparison of Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block With Lateral Femoral Cutaneous Nerve Block (LFCB) Versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB) in Pediatric Hip Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pediatric patients aged between 2 and 16 years.\n* Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries\n* ASA (American Society of Anesthesiologists) physical status classification: I-III.\n* Written informed consent obtained from the patient's legal guardian(s).\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any of the study medications\n* Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.\n* Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.\n* Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.\n* Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.\n* History of chronic opioid use or known substance abuse.\n* Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.","2 Years","16 Years",{"count":286,"type":21},60,[24],"This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.",[290,291,28],"Hip Disease","Hip Dysplasia","2025-07-08",{"date":294,"type":34},"2025-07-11",{"date":296,"type":34},"2025-06-16",{"date":298,"type":21},"2026-06-30",{"name":40,"class":41},{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":42},"100584132","cocrmo-lock-bipolar-femoral-heads-fu-100584132","NCT06885359","CoCrMo LOCK Bipolar Femoral Heads FU","A Post-market Study Evaluating Clinical and Safety Outcomes of Bipolar Hemiarthroplasty Using CoCrMo LOCK Bipolar Femoral Heads in Subjects with Hip Fracture","Inclusion Criteria:\n\n* Displaced intracapsular hip fracture (Garden III-IV).\n* Subjects underwent a Bipolar Hemiarthroplasty with a CoCrMo LOCK Bipolar femoral head as per their Indication For Use from January 1st, 2023, onwards.\n* No concurrent joint disease at the time of the surgery.\n* Absence of severe cognitive dysfunction demonstrated by 3 or more correct answers on the Pfeiffer test.\n* Ability to ambulate independently with or without walking aids before surgery.\n* Subject willingness to participate.\n\nExclusion Criteria:\n\n* Undisplaced or minimally displaced intracapsular hip fracture (Garden I-II).\n* Any CoCrMo LOCK Bipolar femoral head contraindication for use as reported in the current Instruction For Use.\n* Pathological fracture secondary to malignant disease.\n* Subjects with rheumatoid arthritis or symptomatic osteoarthritis.\n* Previous treatment to the same hip for a fracture at the time of the surgery.\n* Subjects who were deemed unsuitable for the surgical procedures by the anesthesiologist.\n* Severe cognitive dysfunction or cognitive impairment demonstrated by 2 or less correct answers on the Pfeiffer test.\n* Unable to walk before surgery (e.g., wheelchair or bed-ridden subjects).",{"count":286,"type":21},"Study design: monocentric, retrospective, observational and post-market clinical study.\n\nPurpose: To demonstrate the safety and performance of CoCrMo LOCK bipolar femoral heads. The eligible study population is represented by the entire population that underwent a hip replacement with CoCrMo LOCK bipolar femoral heads from 1st January 2023 onwards at the site in accordance with the indication for use of the product.",[310,28],"Femoral Fractures",[312,313],"Femoral head","Partial Hip Arthroplasty","2025-03-24",{"date":316,"type":34},"2025-03-26",{"date":318,"type":21},"2025-10",{"date":320,"type":21},"2028-12",{"name":322,"class":92},"Limacorporate S.p.a",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":255,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":42},"100418513","phase-4-the-pericapsular-nerve-block-in-total-hip-arthroplasty-100418513","NCT04729686","The Pericapsular Nerve Block in Total Hip Arthroplasty","The Pericapsular Nerve Block in Total Hip Arthroplasty: A Randomized, Controlled Trial","PENG","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach\n* ASA score of 1 to 3\n* Indicated for one of the two nerve block groups\n* Must be opioid naïve at screening as defined by the FDA - According to the Food and Drug Administration, opioid-tolerant patients were those currently receiving or who had previously received 60 mg PO morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg PO oxycodone per day, 8 mg PO hydromorphone per day, 25 mg PO oxymorphone per day, 60 mg PO hydrocodone per day, or an equivalent dose of another opioid for a duration of one week or longer (16)\n\nExclusion Criteria:\n\n* Current or previous diagnosis of \"chronic pain\"\n* Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)\n* Diagnosis of ankylosing spondylitis\n* Allergy to any potential medications utilized in any of the two groups\n* Conversion of patient to general anesthesia intraoperatively\n* Treatment with another investigational drug or other intervention for pain\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation",{"count":332,"type":21},78,[24],"In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.",[27,28],[337,338,339,340,341],"Total Hip Arthroplasty","Total Hip Replacement","Hip Arthroplasty","Hip Replacement","Postoperative Pain","2025-01-20",{"date":344,"type":34},"2025-01-22",{"date":346,"type":34},"2020-12-09",{"date":348,"type":21},"2025-12-01",{"name":350,"class":41},"LifeBridge Health",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":373},"100549325","polyethylene-wear-particle-analysis-of-tha-100549325","NCT06432543","Polyethylene Wear Particle Analysis of THA","Polyethylene Wear Particle Analysis of Total Hip Arthroplasty -International Multicenter Study-","Inclusion Criteria:\n\n1. Patients undergoing revision hip arthroplasty within the study period\n2. Patients over 20 years old\n3. Patients who have received a sufficient explanation, have sufficient understanding, and have given their free written consent.\n4. Patients who have passed 2 years or more since their first total hip arthroplasty\n\nExclusion Criteria:\n\n1\\. Patients who are judged to be unsuitable as research subjects by the research physician","20 Years",{"count":20,"type":21},"Purpose of research The purpose of this study was to demonstrate that polyethylene (Vitamin E-containing polyethylene), a newly introduced biomaterial for tibial inserts in hip replacement surgery and widely used clinically, but whose mid- to long-term clinical results are still unknown, is superior to conventional polyethylene in vivo. The aim of this project is to conduct an international multi-center joint research study to determine whether polyethylene wear debris production can be reduced in the future, using an in vivo polyethylene wear debris analysis method that the investigators developed as a method that can provide early feedback.",[362,28],"Wear of Articular Bearing Surface of Prosthetic Joint",[364,365],"Polyethylene wear particle","Total hip arthroplasty","2025-01-16",{"date":342,"type":34},{"date":369,"type":34},"2024-06-01",{"date":65,"type":21},{"name":372,"class":41},"Osaka Metropolitan University",2,{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":255,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":42},"100562489","clinical-evaluation-and-cost-effectiveness-analysis-of-3d-digital-surgery-in-traumatology-100562489","NCT06603831","Clinical Evaluation and Cost-effectiveness Analysis of 3D Digital Surgery in Traumatology","Randomized, Prospective and Multicenter Clinical Study for the Clinical Evaluation and Cost-effectiveness Analysis of 3D Digital Surgery in Traumatology and Orthopedic Surgery","Inclusion Criteria:\n\n\\- Patients that requires one of the following surgical procedures \u002F interventions: Radius osteotomy due to non-articular metaphyseal malunion Complex acetabular arthroplasty Thoracic-lumbar spine arthrodesis.\n\n-Patients that can understand the clinical study and that are able to read, understand and sign the consent form\n\nExclusion Criteria:\n\n* Patients that are not able to read, understand or sign the consent form.\n* Patients that can't or have no support to complete the clinical trial.\n* Patients with complex deformities or complications that would require mandatory personalized digital surgery treatment",{"count":382,"type":21},180,[54],"Digital surgery, in combination with patient specific instrumentation (PSI) is being used more and more in traumatology due to its proven benefits and applications. Nowadays, medical case planning and an optimal preparation before surgery are still a challenge for surgeons. This lack of preparation is translated into longer surgical procedures, potential complications, unnecessary sterilization of materials and a high number of fluoroscopies. 2D techniques such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT) and X-rays remain essential for medical planning, however, in many cases, a 3D visualization is needed to achieve better results, especially in complex cases.The use of personalized medical instruments such as surgical guides has proven to increase clinical accuracy, assuring a better correction of bone deformities, and allowing a more precise location of implants and screw positioning. Furthermore, the use of 3D-printed patient-specific prosthesis can lead to better clinical outcomes as they reduce the number of complications as well as they present a longer lifespan compared to conventional generic implants.Despite the potential of 3D technology in the medical field, there is still a lack of robust studies that compares clinical benefits between digital surgery and conventional 2D surgery, and its economic impact is still unknown. Thus, the investigators propose this randomized, prospective and multi-center clinical study to evaluate the use of 3D technology in traumatology. The aim of this project is to prove that digital surgery is a cost-effective methodology and therefore it should be adopted by the public health system as a gold standard procedure.",[386,27,387,28,388,389,390,391,392,393,394,395],"Radius; Deformity","Hip Arthritis","Spine Injury","Radius; Anomaly","Vertebra; Degeneration","Vertebral Fracture","Hip Prosthesis Infection","Spinal Fusion","Spine Osteoarthritis","Spinal Deformity","2024-11-08",{"date":398,"type":34},"2024-11-12",{"date":400,"type":34},"2024-10-21",{"date":402,"type":21},"2027-12-31",{"name":404,"class":41},"Corporacion Parc Tauli",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":42},"100540517","pericapsular-nerve-block-versus-intrathecal-morphine-for-analgesia-after-primary-hip-arthroplasty-100540517","NCT06317870","Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty","Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty: a Double Blind, Non-inferiority Study","PENGIT","Inclusion Criteria:\n\n* Male and female patients\n* ASA (American Society of Anaesthesiologists) I-III\n* 18 years of age or older\n* Patients scheduled for elective primary hip arthroplasty\n* Able to give written conformed consent autonomously\n\nExclusion Criteria:\n\n* Refusal or inability to give consent\n* Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone\n* Bleeding diathesis\n* Neurological deficit of the operative side\n* Existing preoperative opioid use\n* Renal insufficiency (GFR\\\u003C30ml\u002Fmin according to the Cockroft-Gault formula)\n* Hepatic insufficiency\n* Pregnant or lactating women",{"count":414,"type":21},80,[54],"The aim of this clinical trial is to compare the analgesic effect of pericapsular nerve block (PENG) with intrathecal morphine in patients scheduled for total hip replacement surgery. The main question to be answered is whether the PENG block is equivalent to intrathecal morphine in reducing postoperative pain.\n\nParticipants will be randomised into two groups. Patients assigned to the PENG group will receive spinal anaesthesia with local anaesthetic (isobaric bupivacaine) alone and a PENG block. Patients assigned to the intrathecal morphine (ITM) group will receive spinal anaesthesia with a mixture of local anaesthetic (isobaric bupivacaine) and morphine (100 mcg) and a sham PENG block to ensure patient blinding.",[418,28,419],"Analgesia","Post Operative Pain",[421,422,423,265],"nerve block","intrathecal morphine","postoperative pain","2024-08-20",{"date":426,"type":34},"2024-08-22",{"date":428,"type":21},"2024-09-10",{"date":430,"type":21},"2027-05-01",{"name":432,"class":41},"Centre Hospitalier Universitaire Vaudois",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":42},"100530001","routine-use-of-negative-pressure-wound-therapy-thr-tkr-rct-100530001","NCT06181097","Routine Use of Negative Pressure Wound Therapy THR TKR RCT","Routine Use of Negative Pressure Wound Therapy in Primary Hip and Knee Arthroplasties; a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients undergoing total knee or total hip arthroplasty at Prince of Wales Hospital, Hong Kong.\n\nExclusion Criteria:\n\n* Patients using steroid, or other immune modulators that is known to affect wound healing, prior surgery to the knee or hip, skin condition such as eczema that would result in poor healing or widen scars, patients with a known significant history of hypertrophic scarring or keloid.",{"count":441,"type":21},82,[54],"Negative pressure wound therapy (NPWT) for post total joint arthroplasty incisions has demonstrated benefits in reducing wound complications. A prospective randomized trial will be conducted including 40 patients who will undergo total knee and total hip arthroplasty. The number of wound complications within 21 days will be recorded. As well, the aesthetic appearance and quality of scarring of the scar will be assessed.",[57,28,445],"Negative Pressure Wound Therapy",[57,28,447,448,449],"TKR","THR","Wound therapy","2023-12-23",{"date":452,"type":34},"2023-12-29",{"date":454,"type":34},"2023-12-11",{"date":456,"type":21},"2026-12-10",{"name":458,"class":41},"Chinese University of Hong Kong",{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":466,"targetDuration":358,"studyType":77,"phases":4,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":478,"leadSponsor":480,"locationsCount":42},"100495703","promis-evaluation-study-100495703","NCT05734651","PROMIS Evaluation Study","Prospective Evaluation of the PROMIS Stem for Primary Total Hip Arthroplasty","Inclusion Criteria:\n\n* Primary total hip arthroplasty with the PROMIS stem\n\nExclusion Criteria:\n\n* n\u002Fa",{"count":467,"type":21},200,"A total of 250 total hip arthroplasties (THA) are performed at the Bezirkskrankenhaus St. Johann. In a majority of those, implants from the company Falcon Medical (Austria) are used. Those implants are undergoing constant development and improvement. To guarantee their clinical performance, this clinical study is evaluating safety and efficacy of all implants produced by Falcon Medical.\n\nThe purpose of this study is to evaluate the effcacy and safety of implants produced and distributed by Falcon Medical. All patients with primary THA and usage of a Falcon Medical implant are included. The outcome measures include intra-operative complications, early post-operative complications, revision for any cause and patient reported outcome (WOMAC questionnaire). All data is prospectively collected in a standardized fashion.",[28,470,471,472,473],"Osteoarthritis, Hip","Perthes Disease","Osteonecrosis","Femoral Neck Fractures","2023-02-09",{"date":476,"type":34},"2023-02-21",{"date":474,"type":34},{"date":479,"type":21},"2042-02-09",{"name":481,"class":41},"Bezirkskrankenhaus St. Johann in Tirol"]